HKSE · 9688.HK
Zai Lab Limited
HK$17.55-HK$0.13 (-0.74%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.07% below the high.
Loading market information…
HKSE · 2595.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
GenFleet Therapeutics (Shanghai) Inc.’s next earnings report is currently expected on Mar 24, 2027, with estimated earnings per share of -HK$0.78. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow GenFleet Therapeutics (Shanghai) Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
HK$17.55-HK$0.13 (-0.74%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.07% below the high.
HK$21.12-HK$0.04 (-0.19%)
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 17.44% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$4.95+HK$0.21 (+4.44%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$6.30-HK$0.05 (-0.71%)
Abbisko Cayman Limited’s quoted price sits in the lower half of its reported 52-week range, 58.28% below the high.
HK$1.58HK$0.00 (0.0%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.62% below the high.
HK$2.84+HK$0.02 (+0.53%)
Antengene Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 54.78% below the high.
